ライフサイエンスコーパス: gonadotropin

1 progesterone metabolites and human chorionic gonadotropin.

2 irculating concentrations of human chorionic gonadotropin.

3 n with a single injection of human chorionic gonadotropin.

4 a) and the hormone-specific beta-subunits of gonadotropin.

5 ey responded efficiently to a single dose of gonadotropins.

6 rtility defects were secondary to suppressed gonadotropins.

7 rd, along with a greater ovarian response to gonadotropins.

8 ehaviors and the control of the secretion of gonadotropins.

9 its expression is regulated directly by the gonadotropins.

10 of gonadotropin-releasing hormone (GnRH) and gonadotropins.

11 ovarian stimulation (up to four cycles) with gonadotropin (301 women), clomiphene (300), or letrozole

12 tal hypogonadotropic hypogonadism, a lack of gonadotropin activity results primarily in the absence o

13 Gonadotropin administration and mating led to pregnancy

14 Subsequent treatment with gonadotropins allowed the generation of mature oocytes c

15 9%; P=0.44) but was lower than the rate with gonadotropin alone (34 of 107, 32%; P=0.006).

16 py (gonadotropin or clomiphene) (P=0.003) or gonadotropin alone (P<0.001) but not with clomiphene alo

17 of LSD1 also impairs induction of chorionic gonadotropin alpha (CGA) and chorionic gonadotropin beta

18 tropin hormone alpha-subunit gene, chorionic gonadotropin alpha (Cga), is responsible for Cga cell-sp

19 compared with those of beta-human chorionic gonadotropin, alpha-fetoprotein, and lactate dehydrogena

20 ts in hallmarks of POI including stereotyped gonadotropin alterations indicative of early menopause,

21 ased blood level of the beta human chorionic gonadotropin and a histopathological examination, the di

22 ys 1, 8, and 15]), patients' human chorionic gonadotropin and alfa-fetoprotein concentrations were me

23 with a favourable decline in human chorionic gonadotropin and alfa-fetoprotein continued BEP (Fav-BEP

24 ly published data sets for annual changes in gonadotropins and estradiol in rainbow trout.

25 at the end of drug administration, and serum gonadotropins and oestradiol measured.

26 ary during the estrous cycle and the role of gonadotropins and ovarian steroid hormones in ESR36 expr

27 gical activity was validated by secretion of gonadotropins and sex steroids.

28 mulation triggered a significant increase in gonadotropins and testosterone levels in Gnaq(d/d) mice.

29 alpha-Fetoprotein, beta-human chorionic gonadotropin, and lactate dehydrogenase had sensitivitie

30 od sampling for thyroid stimulating hormone, gonadotropin, and prolactin deficiencies, whereas for AC

31 TSH is composed of a alpha-subunit common to gonadotropins, and a beta-subunit conferring hormone spe

32 n immune reaction by binding human chorionic gonadotropin antigen to immunoglobulin antibody immobili

33 oprotein and beta-subunit of human chorionic gonadotropin are used as biomarkers for the management o

34 rimary site and the level of human chorionic gonadotropin as independent factors.

35 cts pregnancy using the beta human chorionic gonadotropin (b-hCG) test from both the morphology of an

36 ionic gonadotropin alpha (CGA) and chorionic gonadotropin beta (CGB) genes, which encode alpha and be

37 ndent microRNAs, predicted in silico to bind gonadotropin beta subunit mRNAs, were suppressed in puri

38 t if microRNAs regulate the hormone-specific gonadotropin beta subunits in vivo, we deleted Dicer in

39 a that was confirmed by beta human chorionic gonadotropin (beta-HCG) levels and histopathology.

40 dotropes resulted in profound suppression of gonadotropin-beta subunit proteins and, consequently, th

41 hat have not been previously associated with gonadotropin biosynthesis and/or secretion.

42 er frequency of live birth, as compared with gonadotropin but not as compared with clomiphene.

43 The secretion of chorionic gonadotropin by TSC-derived ST reflects a reprogramming

44 rmatids in the SLL, showing that circulating gonadotropin can reach the intratubular compartment.

45 After treatment with gonadotropin, clomiphene, or letrozole, clinical pregnan

46 arboring SOX2 mutations are at high risk for gonadotropin deficiency, which has important implication

47 ulature relationship maps indicated age- and gonadotropin-dependent increases in vasculature and bran

48 icle block and in response to superovulatory gonadotropins exhibit normal distribution of ovarian fol

49 Pituitary gonadotropins follicle-stimulating hormone and luteinizi

50 ed a single injection of pregnant mare serum gonadotropin followed by progesterone or vehicle.

51 ible for generating the pulsatile release of gonadotropins from the pituitary gland are unknown.

52 on of Homer1 splicing by GnRH contributes to gonadotropin gene control.

53 tone 3 (H3S10p) as part of its regulation of gonadotropin gene expression, possibly involving cross-t

54 e time of GCT diagnosis, and human chorionic gonadotropin >/= 1,000 mIU/mL at initiation of HDCT.

55 fetoprotein (AFP) 2.0 ng/mL, human chorionic gonadotropin (hCG) 151,111 IU/L, and lactate dehydrogena

56 or two model cancer markers, human chorionic gonadotropin (hCG) and prostate specific antigen (PSA),

57 uteinizing hormone (hLH) and human chorionic gonadotropin (hCG) are human glycoprotein hormones each

58 has been demonstrated using human chorionic gonadotropin (hCG) as an example.

59 on expression of syncytial [human chorionic gonadotropin (hCG) beta] and fusogenic [syncytin 1, sync

60 Serum human chorionic gonadotropin (hCG) concentration was 200 mIU/ml; she was

61 d that the pregnancy hormone human chorionic gonadotropin (hCG) efficiently attracts human Tregs to t

62 ompromised mice that secrete human chorionic gonadotropin (hCG) into the host mouse and include small

63 Human chorionic gonadotropin (hCG) is an important biomarker for the dia

64 Human chorionic gonadotropin (hCG) is necessary for the maintenance of e

65 Human chorionic gonadotropin (hCG) is one of the earliest hormones produ

66 not establish a single serum human chorionic gonadotropin (hCG) level that is diagnostic of ectopic p

67 venously every 2 weeks until human chorionic gonadotropin (hCG) normalization, followed by 3 consolid

68 affinity and specificity for human chorionic gonadotropin (hCG) protein.

69 Treatment of mice with human chorionic gonadotropin (hCG) resulted in increased circulating tes

70 In the present work human chorionic gonadotropin (hCG) was used as a model protein in a proo

71 ms of the human pregnancy hormone, chorionic gonadotropin (hCG), in the liver.

72 using the mediator molecule human chorionic gonadotropin (hCG), we interface the intracellular infor

73 for the efficient binding of Human Chorionic Gonadotropin (hCG).

74 8.0 ug/L), and a normal beta-human chorionic gonadotropin (HCG).

75 performance enhancing drug, human chorionic gonadotropin (hCG).

76 ntracellular beta subunit of human chorionic gonadotropin (hCGbeta) and peroxisome proliferator activ

77 uction of aromatase (hCYP19A1) and chorionic gonadotropin (hCGbeta) expression.

78 DICER-dependent microRNAs are essential for gonadotropin homeostasis and fertility in mice.

79 The distal enhancer of the gonadotropin hormone alpha-subunit gene, chorionic gonad

80 circuit that evokes the pulsatile release of gonadotropin hormones (luteinizing hormone and follicle-

81 imulate synthesis and secretion of pituitary gonadotropin hormones and thereby mediate control of rep

82 Pituitary gonadotropin hormones are regulated by gonadotropin-rele

83 reproduction by regulating expression of the gonadotropin hormones, which are responsible for follicl

84 l sexual behavior but hypothalamic-pituitary-gonadotropin (HPG) axis dysregulation, likely explaining

85 iated with irregular reproductive cyclicity, gonadotropin imbalance, and impaired reproductive capabi

86 inbow trout and new data on the synthesis of gonadotropins in the pituitary.

87 ed pups, whereas administration of exogenous gonadotropins induced normal ovulation in these mice.

88 hat low doses of exogenous androgens enhance gonadotropin-induced ovulation in mice, further demonstr

89 peptide receptors, including neuropeptide Y, gonadotropin inhibitory hormone (GnIH), pyroglutamylated

90 Gonadotropin-inhibitory hormone (GnIH) acts as a negativ

91 Recently, gonadotropin-inhibitory hormone (GnIH) has emerged as an

92 -related peptides (RFRPs) are orthologous to gonadotropin-inhibitory hormone (GnIH) inhibiting gonado

93 Gonadotropin-inhibitory hormone (GnIH) is a neuropeptide

94 with testosterone or in vitro treatment with gonadotropin-inhibitory hormone (GnIH) reduced GnRH rele

95 s, gonadotropin-releasing hormone (GnRH) and gonadotropin-inhibitory hormone (GnIH), respectively, re

96 ted peptide-3 [RFRP-3; mammalian ortholog to gonadotropin-inhibitory hormone (GnIH)] in neuroendocrin

97 Inhibitory action of gonadotropin-inhibitory hormone on the signaling pathway

98 ind increased follicle numbers and decreased gonadotropin levels in aging FOXO3-transgenic mice compa

99 serum alpha-fetoprotein and human chorionic gonadotropin levels were normal.

100 F alpha-fetoprotein and beta-human chorionic gonadotropin levels were not associated with PFS.

101 a marked decrease in secretion of pituitary gonadotropins LH and FSH and impairment of reproductive

102 Maximal secretion of the gonadotropin Luteinizing Hormone is supported by GLUT1 e

103 ormone analogs [n = 38 653], human chorionic gonadotropin [n = 68 181], progesterone [n = 41 628], an

104 of fertility drugs (clomiphene [n = 33 835], gonadotropins [n = 57 136], gonadotropin-releasing hormo

105 NAP fusion reporter protein (human chorionic gonadotropin-O(6) -alkylguanine-DNA alkyltransferase) le

106 f 100 ng/mL or greater or of human chorionic gonadotropin of 5,000 U/L or greater (group B) were addi

107 ce and highly elevated serum human chorionic gonadotropin or alfa-fetoprotein concentrations that mat

108 not differ significantly from the rate with gonadotropin or clomiphene (42 of 192, 22%; P=0.15) or c

109 py for women with unexplained infertility is gonadotropin or clomiphene citrate.

110 lower than the rates with standard therapy (gonadotropin or clomiphene) (P=0.003) or gonadotropin al

111 oocyte maturation, whereas the daily dose of gonadotropin or the total number of metaphase II oocytes

112 produce extensive amounts of human chorionic gonadotropin, progesterone, placental growth factor, and

113 s unique to the ovary because in the testes, gonadotropin receptors are expressed in separate compart

114 ypes and maintained responsiveness to KP and gonadotropins reflect Galphaq/11-independent GnRH secret

115 Gonadotropin Regulated Testicular Helicase (GRTH/DDX25),

116 Gonadotropin-regulated testicular RNA helicase (GRTH/DDX

117 diol replacement after ovariectomy inhibited gonadotropin release to a similar extent in both groups.

118 tion, insufficient energy reserves attenuate gonadotropin release, leading to infertility.

119 otropin-inhibitory hormone (GnIH) inhibiting gonadotropin release.

120 direct hypophysiotropic effect on pituitary gonadotropin release.

121 he coordination of sex-specific behavior and gonadotropin release.

122 In gonadotropin-release experiments, dendrimer 3 was shown

123 17beta-estradiol (E2) regulating release of gonadotropin releasing hormone (GnRH) and luteinizing ho

124 zed by absent puberty and infertility due to gonadotropin releasing hormone (GnRH) deficiency, which

125 Release of gonadotropin releasing hormone (GnRH) from the medial ba

126 stone deacetylases (HDACs) in the control of gonadotropin releasing hormone (GnRH) neuronal developme

127 odulate the central driver of fertility: the gonadotropin releasing hormone (GnRH) neuronal system.

128 onadotropic hypogonadism to study effects of gonadotropin releasing hormone (GnRH) neurons on neurona

129 e associated with regulation by activins and gonadotropin releasing hormone (GnRH).

130 Gonadotropin releasing hormone antagonism successfully r

131 o the antral stage in both immature mice and gonadotropin releasing hormone antagonist-treated adult

132 differences in T through administration of a gonadotropin releasing hormone antagonist.

133 ive control, including direct innervation of gonadotropin releasing hormone neurons.

134 Pharmacoperones of the gonadotropin releasing hormone receptor (GnRHR) have eff

135 in-conjugated gold nanorods (gGNRs) promotes gonadotropin releasing hormone receptor-mediated interna

136 onsiveness to the endogenous natural ligand, gonadotropin releasing hormone, and an agonist that is s

137 Finasteride and gonadotropin-releasing analogues are associated with inc

138 acetate, a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH or LHRH), is the ac

139 Gonadotropin-releasing hormone (GnRH) agonists (e.g., tr

140 Studies of the use of gonadotropin-releasing hormone (GnRH) agonists to protec

141 n were on antiandrogens (AA), 26,959 were on gonadotropin-releasing hormone (GnRH) agonists, and 3,74

142 Women treated with gonadotropin-releasing hormone (GnRH) analogs may develo

143 estrogens, finasteride, spironolactone, and gonadotropin-releasing hormone (GnRH) analogs.

144 Both gonadotropin-releasing hormone (GnRH) and activins, memb

145 ted with oocyte meiosis, TGF-beta signaling, gonadotropin-releasing hormone (GnRH) and epidermal grow

146 In vertebrates, gonadotropin-releasing hormone (GnRH) and gonadotropin-i

147 and controls the synthesis and/or release of gonadotropin-releasing hormone (GnRH) and gonadotropins.

148 Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produc

149 Dysfunction of the gonadotropin-releasing hormone (GnRH) axis causes a rang

150 Individuals with an inherited deficiency in gonadotropin-releasing hormone (GnRH) have impaired sexu

151 Gonadotropin-releasing hormone (GnRH) is a key regulator

152 Gonadotropin-releasing hormone (GnRH) is a trophic pepti

153 Gonadotropin-releasing hormone (GnRH) is a trophic pepti

154 Gonadotropin-releasing hormone (GnRH) is secreted in bri

155 Gonadotropin-releasing hormone (GnRH) is secreted in bri

156 The gonadotropin-releasing hormone (GnRH) is the master regu

157 The gonadotropin-releasing hormone (GnRH) is the master regu

158 posed to pulsatile, delivery of hypothalamic gonadotropin-releasing hormone (GnRH) leads to a marked

159 We have previously shown that gonadotropin-releasing hormone (GnRH) ligand-independent

160 (RFRP-3) neurons have been shown to inhibit gonadotropin-releasing hormone (GnRH) neuronal activity

161 a profound influence on the activity of the gonadotropin-releasing hormone (GnRH) neuronal network c

162 isspeptin is a key regulator of hypothalamic gonadotropin-releasing hormone (GnRH) neurons and is ess

163 Estradiol feedback regulates gonadotropin-releasing hormone (GnRH) neurons and subseq

164 diol alters both the intrinsic properties of gonadotropin-releasing hormone (GnRH) neurons and synapt

165 Gonadotropin-releasing hormone (GnRH) neurons are neuroe

166 Gonadotropin-releasing hormone (GnRH) neurons are the fi

167 The gonadotropin-releasing hormone (GnRH) neurons are the ke

168 Central output of gonadotropin-releasing hormone (GnRH) neurons controls f

169 oductive functioning in mammals depends upon gonadotropin-releasing hormone (GnRH) neurons generating

170 in mice for controlling the activity of the gonadotropin-releasing hormone (GnRH) neurons in vivo to

171 Gonadotropin-releasing hormone (GnRH) neurons originate

172 Gonadotropin-releasing hormone (GnRH) neurons produce th

173 Gonadotropin-releasing hormone (GnRH) neurons regulate p

174 onstructions and electrophysiology, that the gonadotropin-releasing hormone (GnRH) neurons that contr

175 rculating estradiol on proestrus to activate gonadotropin-releasing hormone (GnRH) neurons that, in t

176 s how nerve terminal Ca(2+) is controlled in gonadotropin-releasing hormone (GnRH) neurons via action

177 peptin regulates reproduction by stimulating gonadotropin-releasing hormone (GnRH) neurons via the ki

178 ARH)), which drive the pulsatile activity of gonadotropin-releasing hormone (GnRH) neurons.

179 TEMENT The brain regulates fertility through gonadotropin-releasing hormone (GnRH) neurons.

180 f reproduction by acting on gonadotropes and gonadotropin-releasing hormone (GnRH) neurons.

181 icating abnormal steroid hormone feedback to gonadotropin-releasing hormone (GnRH) neurons.

182 , is enriched in cilia projecting from mouse gonadotropin-releasing hormone (GnRH) neurons.

183 o adulthood and depends upon the activity of gonadotropin-releasing hormone (GnRH) neurons.

184 The brain regulates fertility through gonadotropin-releasing hormone (GnRH) neurons.

185 Hypothalamic gonadotropin-releasing hormone (GnRH) plays a critical r

186 lth and wellbeing.SIGNIFICANCE STATEMENT The gonadotropin-releasing hormone (GnRH) pulse generator co

187 Fertility critically depends on the gonadotropin-releasing hormone (GnRH) pulse generator, a

188 The gonadotropin-releasing hormone (GnRH) receptor is a drug

189 ion as a measure of information transfer via gonadotropin-releasing hormone (GnRH) receptors (GnRHR)

190 ement during lethargus, by signaling through gonadotropin-releasing hormone (GnRH) related receptors.

191 ance and obesity are associated with reduced gonadotropin-releasing hormone (GnRH) release and infert

192 t the release of kisspeptin, which modulates gonadotropin-releasing hormone (GnRH) release from GnRH

193 important in modulating the tonic pulsatile gonadotropin-releasing hormone (GnRH) release.

194 of reproduction by brain-secreted pulses of gonadotropin-releasing hormone (GnRH) represents a longs

195 suggests that MKRN3 is acting as a brake on gonadotropin-releasing hormone (GnRH) secretion during c

196 uberty is orchestrated by an augmentation of gonadotropin-releasing hormone (GnRH) secretion from a f

197 Acquisition of a mature pattern of gonadotropin-releasing hormone (GnRH) secretion from the

198 Gonadotropin-releasing hormone (GnRH) secretion is regul

199 mammalian reproduction as key regulators of gonadotropin-releasing hormone (GnRH) secretion.

200 Crz belongs to gonadotropin-releasing hormone (GnRH) superfamily, imply

201 ic focus was on ligands and receptors of the gonadotropin-releasing hormone (GnRH) superfamily.

202 lmann syndrome is an inherited deficiency of gonadotropin-releasing hormone (GnRH) that is characteri

203 revealed that IKK-beta and NF-kappaB inhibit gonadotropin-releasing hormone (GnRH) to mediate ageing-

204 itary gonadotropin hormones are regulated by gonadotropin-releasing hormone (GnRH) via MAPK signaling

205 duce ciliated neurons that express genes for gonadotropin-releasing hormone (GnRH), a G-protein-coupl

206 ) designed to express an antibody that binds gonadotropin-releasing hormone (GnRH), a master regulato

207 (MCH), thyrotropin-releasing hormone (TRH), gonadotropin-releasing hormone (GnRH), and kisspeptin.

208 sprouting in hypothalamic neurons secreting gonadotropin-releasing hormone (GnRH), the neuropeptide

209 Gonadotropin-releasing hormone (GnRH)-expressing neurons

210 n mammals by secreting the 'master molecule' gonadotropin-releasing hormone (GnRH).

211 ted as an increase in pulsatile secretion of gonadotropin-releasing hormone (GnRH).

212 ontrols reproduction in mammals by secreting gonadotropin-releasing hormone (GnRH).

213 e reproduction requires pulsatile release of gonadotropin-releasing hormone (GnRH1) from the hypothal

214 In mammals, the receptor of the neuropeptide gonadotropin-releasing hormone (GnRHR) is unique among t

215 Gene expression of salmon gonadotropin-releasing hormone (sGnRH) and NR1 increased

216 to provide an episodic, excitatory drive to gonadotropin-releasing hormone 1 (GnRH) neurons, the syn

217 nit, which is transcriptionally regulated by gonadotropin-releasing hormone 1 (GNRH).

218 asic ovarian sex hormone fluctuation using a gonadotropin-releasing hormone agonist (GnRHa) and evalu

219 rted previously that after 1-year follow up, gonadotropin-releasing hormone agonist (GnRHa) did not p

220 by surgical castration and those who receive gonadotropin-releasing hormone agonist (GnRHa) therapy.

221 nditions: ovarian suppression induced by the gonadotropin-releasing hormone agonist leuprolide acetat

222 Gonadotropin-releasing hormone agonist therapy is associ

223 over study, 12 healthy, young males received gonadotropin-releasing hormone agonist treatment 1 month

224 nditions: ovarian suppression induced by the gonadotropin-releasing hormone agonist, leuprolide aceta

225 The authors examined the effects of gonadotropin-releasing hormone agonist-induced ovarian s

226 ntraindication to tamoxifen may be offered a gonadotropin-releasing hormone agonist/antagonist plus a

227 Gonadotropin-releasing hormone agonists (GnRHa) have bee

228 Puberty suppression by gonadotropin-releasing hormone agonists (GnRHa), such as

229 herapies (OR, 4.04 [95% CI, 1.88-8.69]), and gonadotropin-releasing hormone agonists (OR, 1.93 [95% C

230 androgen deprivation therapy in the form of gonadotropin-releasing hormone agonists and newer antago

231 Gonadotropin-releasing hormone agonists given with chemo

232 y a combined androgen blockade consisting of gonadotropin-releasing hormone agonists with oral antian

233 rized into 1 of 6 mutually exclusive groups: gonadotropin-releasing hormone agonists, oral antiandrog

234 ne [n = 33 835], gonadotropins [n = 57 136], gonadotropin-releasing hormone analogs [n = 38 653], hum

235 Gonadotropin-releasing hormone analogue triptorelin, bil

236 rel-releasing intrauterine system (LNG-IUD), gonadotropin-releasing hormone analogues (GnRHa; nafarel

237 Gonadotropin-releasing hormone analogues and laparoscopi

238 n suppression (castration via orchiectomy or gonadotropin-releasing hormone analogues) suppresses cir

239 Gonadotropin-releasing hormone analogues, danazol, and d

240 ikely to be mediated by reduced secretion of gonadotropin-releasing hormone and our results support t

241 Elagolix, an oral gonadotropin-releasing hormone antagonist resulting in r

242 le-stimulating hormone and administration of gonadotropin-releasing hormone antagonist to prevent pre

243 he efficacy and safety of relugolix, an oral gonadotropin-releasing hormone antagonist, as compared w

244 levels are increased somewhat by exposure to gonadotropin-releasing hormone but are not necessarily l

245 st gonadotropin responses, suggesting normal gonadotropin-releasing hormone neuronal and gonadotrope

246 lamic nucleus and send axonal projections to gonadotropin-releasing hormone neurons and regulate repr

247 sspeptin neurons relay estradiol feedback to gonadotropin-releasing hormone neurons, which regulate t

248 ive Ca(2+) imaging in the nerve terminals of gonadotropin-releasing hormone neurons.

249 targeting of tumor cells overexpressing the gonadotropin-releasing hormone receptor (GnRH-R).

250 icipate in partitioning mutant conformers of gonadotropin-releasing hormone receptor (GnRHR), a G pro

251 oral contraceptives/antagonization of human gonadotropin-releasing hormone receptor [hGnRH-R] activi

252 s capable of rescuing the activity of mutant gonadotropin-releasing hormone receptor or GnRHR which,

253 oter activity, highlighting a role of SET in gonadotropin-releasing hormone regulation of gene expres

254 from the Kiss1 promoter disrupted pulsatile gonadotropin-releasing hormone release, delayed puberty

255 androgen receptors, and by the hypothalamic gonadotropin-releasing hormone through activation of PKA

256 olic, and other factors control secretion of gonadotropin-releasing hormone to determine initiation o

257 uires the pulsatile, coordinated delivery of gonadotropin-releasing hormone to the pituitary and the

258 In the BPD mouse model, gonadotropin-releasing hormone was increased in females

259 a neuropeptide homologous to the vertebrate gonadotropin-releasing hormone, is downregulated as work

260 nsgenic mice, and is released in response to gonadotropin-releasing hormone, similar to LH.

261 uctive function requires timely secretion of gonadotropin-releasing hormone, which is controlled by a

262 ultimately drive the pulsatile secretion of gonadotropin-releasing hormone.

263 production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin, ooph

264 During mammalian development, gonadotropin-releasing-hormone-1 neurons (GnRH-1ns) migr

265 In particular, gonadotropin replacing hormone (GnRH) is released in rhy

266 re;Lepr(lox/lox) female mice elicited robust gonadotropin responses, suggesting normal gonadotropin-r

267 ovarian follicle development and antagonizes gonadotropin responsiveness in granulosa cells by suppre

268 a key regulator of follicle development and gonadotropin responsiveness.

269 a key regulator of follicle development and gonadotropin responsiveness.-Abedini, A., Zamberlam, G.,

270 GnRH regulates the pituitary gonadotropin's follicle-stimulating hormone (FSH) and lu

271 othesis that a NKB antagonist would decrease gonadotropin secretion and inhibit folliculogenesis in h

272 low oxygen leads to reduced human chorionic gonadotropin secretion and STB-associated gene expressio

273 owever, only GATAD1 abundance increases when gonadotropin secretion is suppressed during late infancy

274 Chorionic gonadotropin secretion was > 4000-fold higher in ST cult

275 in birds and mammals by inhibiting GnRH and gonadotropin secretion.

276 H) neurons generating a pulsatile pattern of gonadotropin secretion.

277 ssociation with the pubertal reactivation of gonadotropin secretion.

278 ensitisation of Smad signaling and increased gonadotropin sensitivity along with a significant reduct

279 NT5a functions as a physiologic inhibitor of gonadotropin signaling.

280 the carboxyterminal heptapeptide in LH is a gonadotropin-sorting determinant in vivo that directs pu

281 ular basis for this evolutionarily conserved gonadotropin-specific secretion pattern is not understoo

282 er IVF cycle included the usual cocktail for gonadotropin stimulation and was uncomplicated, except f

283 ed in GCs and its expression is modulated by gonadotropin stimuli.

284 Here we studied the expression profile of gonadotropin subunit and GnRH receptor genes in rat pitu

285 Although transcriptional regulation of gonadotropin subunits has been well studied, the post-tr

286 died, the post-transcriptional regulation of gonadotropin subunits is not well understood.

287 and extragonadal androgen actions (including gonadotropin suppression and sexual behavior) were asses

288 Inhibition of the gonadotropin surge by phenobarbital treatment on D4:1100

289 signaling in the regulation of the ovulatory gonadotropin surge, a result at variance with experiment

290 e post-gonadectomy-induced rise in pituitary gonadotropin synthesis and secretion were both abolished

291 ate microRNAs in gonadal feedback control of gonadotropin synthesis and secretion.

292 y defined by a positive beta human chorionic gonadotropin test, two weeks after insemination.

293 ute levels, effects the release of pituitary gonadotropins that drive steroid production in the gonad

294 women with low responses to the traditional gonadotropin therapy.

295 negative feedback of exogenous T to suppress gonadotropins, thereby blocking the testicular T product

296 pendently or additively with human chorionic gonadotropin to enhance androstenedione secretion.

297 ene and letrozole groups were twins, whereas gonadotropin treatment resulted in 24 twin and 10 triple

298 collected from women between days 3 and 9 of gonadotropin treatment.

299 subtype and increase of beta-human chorionic gonadotropin were not significantly correlated with wors

300 would maintain sexual function and suppress gonadotropins without simultaneously activating spermato